HONG KONG, Nov. 16, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) announced that its AK152, a novel bispecific antibody targeting both amyloid-beta (Aβ) and blood-brain barrier (BBB) expressed receptor, has been granted approval by the National Medical Products Administration (NMPA) to...
Hence then, the article about akeso s bispecific antibody targeting ab and bbb expressed receptor approved for alzheimer s disease clinical trials in china was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's Bispecific Antibody Targeting Aβ and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China )
Also on site :
- Here’s What Jack Schlossberg Had to Say About Madonna’s Recent Revelations on JFK Jr. as a Lover: ‘All I Can Say Is…’
- ’90s Rock Band Extends 2026 Tour With Special Guests
- Sam Bankman-Fried formally files for pardon—but White House reiterates that FTX cofounder’s odds are slim